SmPC (Summary of Product Characteristics)

Updated 2026-07-13 · markdown version

The SmPC (Summary of Product Characteristics) is the legally approved EU/UK document that defines what a medicine is for regulatory purposes: licensed indications, posology, contraindications, warnings, interactions, adverse reactions. In European promotional review, the SmPC is the anchor document — claims must be consistent with it, and promotion beyond it is off-label by definition.

The SmPC plays the role that approved labeling (the USPI) plays in the US, and the constructs differ accordingly: the US pairs claims with fair balance and ISI blocks, while UK/EU review checks claim-by-claim consistency with the SmPC and the Code's prescribing-information requirements. An SmPC update — new warning, revised indication — instantly stales every deliverable and claims matrix row that touched the changed section, making "PI/SmPC change triage" one of the highest-value maintenance rituals in medical communications.

Cross-market note for writers: a claim substantiated against US labeling is not automatically usable in Europe. Regime-tag your claims matrix; the fastest route to a failed UK certification is importing a US deck wholesale. See MLR vs Copy Approval.